跳至主要内容
临床试验/NCT06785324
NCT06785324招募中不适用

Nutrition and Exercise to Optimize Muscle and Adiposity in Adults With ALL: NEOMA ALL Trial

University of Chicago1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年5月12日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
1
主要终点
Feasibility of nutrition and exercise intervention

研究概览

简要总结

This clinical trial aims to assess the effect of nutrition and exercise on muscle and adiposity in adults with Philadelphia Chromosome (Ph) Negative B-ALL undergoing inpatient induction therapy.

Participants will take part in 2 different interventions:

  • Nutrition Intervention
  • Physical Exercise Intervention

All subjects will be provided with a wearable electronic activity monitor (FitBit®) to assist in recording activity levels in minutes of activity.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •New Diagnosis of Philadelphia Chromosome Negative B-ALL
  • •Receiving intensive pediatric-inspired induction chemotherapy

排除标准

  • •BMI ≤18.5 kg/m2 at time of diagnosis
  • •Unable to comply with both the recommended diet and exercise regimen as deemed by the research or treatment team

研究组 & 干预措施

Nutrition and Exercise interventions

Experimental

Participants will receive an exercise and nutrition (diet) intervention while hospitalized for routine treatment for their ALL.

干预措施: Nutrition Intervention (Behavioral)

Nutrition and Exercise interventions

Experimental

Participants will receive an exercise and nutrition (diet) intervention while hospitalized for routine treatment for their ALL.

干预措施: Exercise intervention (Behavioral)

结局指标

主要结局

Feasibility of nutrition and exercise intervention

时间窗: End of study recruitment (approximately 1 year)

Percentage of eligible patients that consent to trial.

次要结局

  • Adherence to dietary intervention(22 days)
  • Adherence to exercise intervention(22 days)
  • Usability of interventions(22 days)
  • Body composition changes - Visceral Adiposity(22 days)
  • Body composition changes - Sarcopenia (SMI)(22 days)
  • Impact on minimal residual disease (MRD)(22 days)
  • Impact on Treatment toxicities(22 days)
  • Changes to the Host Metabolome(22 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验